Covid 19 Breakthrough Infections Remain Rarely Seen In Some Cases

COVID-19 is a combination of two medicines, glecaprevir and pibrentasvir. It helps people who have been treated for chronic Hepatitis C but still have high levels of the virus in their body when they

Covid 19 Breakthrough Infections Remain Rarely Seen In Some Cases

Patients with chronic Hepatitis C can take COVID-19 regimen to avoid breakthrough infections. The treatment has been approved by the FDA. COVID-19 regimen is a combination of two medicines, glecaprevir and pibrentasvir. Both medicines are used in people who have been treated for chronic Hepatitis C but still have high levels of the virus in their body when they stop taking their treatment. It is best to take the medicine with other antiviral medicine to help prevent breakthrough infections and damage to the liver. Read on to learn more about this new drug and whether or not it may be right for

What is COVID-19?

Developed by Samsung Bioepis, the new drug, which is called the COVID-19, comes as a combination of two drugs, glecaprevir and pibrentasvir. Glecaprevir helps the virus replicate and infect new blood cells, while pibrentasvir stops the virus from replicating. A recent report of the Infectious Diseases Society of America (IDSA) had stated that there are only three known cases of patients who developed breakthrough infections, when they stopped taking the single-drug therapy and began taking the combo therapy. It is important to mention that the three patients came from Canada, Hungary, and Poland, where the drug had been used in combination therapy for some time.

When to take COVID-19

Hepatitis C is a bloodborne viral infection caused by the hepatitis C virus. A person with Hepatitis C can live with it for several years before experiencing symptoms. It is possible for the hepatitis C infection to stay in the body for years without anyone knowing about it. But people who have it can experience such symptoms as feeling sick, being tired, and being dehydrated. Not everyone who is infected by the hepatitis C virus will go on to develop any symptoms. The good news is that people with it don’t usually have long-term side effects from it. However, for people who have chronic Hepatitis C, they might develop cirrhosis, liver cancer, or liver failure, even if they do not have any symptoms from the hepatitis C infection.

Advantages of using COVID-19

Patients should take COVID-19 in a combination with other anti-viral medicines in order to reduce the risk of infections. The COVID-19 regimen does not have any serious side effects like the ones associated with other treatment, such as interferon, ribavirin, and sorafenib. COVID-19 was launched in 2015 to treat chronic Hepatitis C infection. However, because of the shortage of supply of the medicine, it was taken off the market in 2017. However, due to a new manufacturing deal, COVID-19 has now been made available to patients again. Because of the shortage of supply of the drug, several patients died before they could get the treatment. This makes the treatment all the more important.

Disadvantages of using COVID-19

Patients must take the medicines for at least 12 weeks, every 2 weeks. Patients taking the medicines for chronic Hepatitis C will need to take the medicine for a long time. However, a new study has reported that there may be some other important side-effects of taking the drug. Patients taking the COVID-19 regimen can have moderate to severe headaches. Also, most patients taking the drug will be given a dose of steroids before the next treatment. Drugs taken with other medicines to treat other viruses are considered to be non-promising for patients with Hepatitis C. Since many patients who have chronic Hepatitis C face other medical complications, it is better to use the combination treatment of COVID-19 and other medicine.